Current
$209B
5-Year Average
$338B
All-Time High
$657B
All-Time Low
$15.9B
Market cap daily chart for Novo Nordisk (NVO)
Aug 2, 2021 – Jul 31, 2026 · 1,255 trading days
Market Cap history table for Novo Nordisk (NVO) from 1985 to 2026
| 2026 | — | — | — | ||
| 2025 | — | — | — | ||
| 2024 | — | — | — | ||
| 2023 | — | — | — | ||
| 2022 | — | — | — | ||
| 2021 | — | — | — | ||
| 2020 | — | — | — | ||
| 2019 | — | — | — | ||
| 2018 | — | — | — | ||
| 2017 | — | — | — | ||
| 2016 | — | — | — | ||
| 2015 | — | — | — | ||
| 2014 | — | — | — | ||
| 2013 | — | — | — | ||
| 2012 | — | — | — | ||
| 2011 | — | — | — | ||
| 2010 | — | — | — | ||
| 2009 | — | — | — | ||
| 2008 | — | — | — | ||
| 2007 | — | — | — | ||
| 2006 | — | — | — | ||
| 2005 | — | — | — | ||
| 2004 | — | — | — | ||
| 2003 | — | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — | ||
| 1989 | — | — | — | ||
| 1988 | — | — | — | ||
| 1987 | — | — | — | ||
| 1986 | — | — | — | ||
| 1985 | — | — | — |
- 2026——
- 2025——
- 2024——
- 2023——
- 2022——
- 2021——
- 2020——
- 2019——
- 2018——
- 2017——
- 2016——
- 2015——
- 2014——
- 2013——
- 2012——
- 2011——
- 2010——
- 2009——
- 2008——
- 2007——
- 2006——
- 2005——
- 2004——
- 2003——
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
- 1989——
- 1988——
- 1987——
- 1986——
- 1985——
Market Cap values are taken from Novo Nordisk's reported income statements (share counts) and end-of-day prices (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Market Cap at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's latest reported market cap is $163B. Market capitalization is the total dollar value of all outstanding shares — shares outstanding × stock price — and the standard measure of a company's equity value. On this page, historical market cap snaps filing-period share counts to closing prices on or before each statement date (not intraday tick data).
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2026, Novo Nordisk (NVO) market cap totalled $209B – declined 7.5% year-over-year.
Over 2021–2026 (5 years), Novo Nordisk market cap expanded at a -4.1% compound annual rate, with a net decline across the window.
Novo Nordisk market cap peaked at $465B in 2023; the latest annual figure is $209B in 2026 (55.0% below peak).
$465B stands as the all-time-high annual market cap, posted in 2023, against a low of $543M during 1987.
Novo Nordisk Market Cap by Year
Novo Nordisk Market Cap 2026: $209B
2026's market cap for Novo Nordisk came in at $209B, declined 7.5% below 2025.
Novo Nordisk Market Cap 2025: $226B
Novo Nordisk posted market cap of $226B in 2025, plunged 41.1% below 2024.
Novo Nordisk Market Cap 2024: $384B
In 2024, Novo Nordisk reported market cap of $384B, declined 17.4% below 2023.
Novo Nordisk Market Cap 2023: $465B
Novo Nordisk market cap in 2023 was $465B, surged 51.2% from 2022. This figure represents the highest annual value in the available history.
Novo Nordisk Market Cap 2022: $308B
Novo Nordisk market cap in 2022 was $308B.
See more financial history for Novo Nordisk (NVO).
Sector peers by Market Cap
Healthcare peers of Novo Nordisk (NVO), ranked by their latest market cap
| $1.08T | |
| $618B | |
| $443B | |
| $376B | |
| $322B | |
| $213B | |
| $208B | |
| $184B |
- $1.08T
- $443B
- $322B
- $208B
Frequently asked questions
Test yourself on NVO
Market Cap — 10 rounds, every one of them NVO against another company. Leave whenever you like.
Practice run — it doesn’t move your skill rating and doesn’t touch the leaderboards. Misses do go into your review queue.
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
- Buybacks0.23% TTM
- Dividend Profile3.83% yield
- Dividend Calculator
- Dividend Forecast
- Dividend Capture
- Stock Split History5 splits
How this company returns cash to shareholders — buybacks, dividends, and stock splits.